<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81856</article-id><article-id pub-id-type="doi">10.7554/eLife.81856</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Tools and Resources</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-286826"><name><surname>Replogle</surname><given-names>Joseph M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-286827"><name><surname>Bonnar</surname><given-names>Jessica L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286828"><name><surname>Pogson</surname><given-names>Angela N</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-227277"><name><surname>Liem</surname><given-names>Christina R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286830"><name><surname>Maier</surname><given-names>Nolan K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6103-6726</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286831"><name><surname>Ding</surname><given-names>Yufang</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286832"><name><surname>Russell</surname><given-names>Baylee J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286833"><name><surname>Wang</surname><given-names>Xingren</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286838"><name><surname>Leng</surname><given-names>Kun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286836"><name><surname>Guna</surname><given-names>Alina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286835"><name><surname>Norman</surname><given-names>Thomas M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-286834"><name><surname>Pak</surname><given-names>Ryan A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286837"><name><surname>Ramos</surname><given-names>Daniel M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-160761"><name><surname>Ward</surname><given-names>Michael Emmerson</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5296-8051</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45861"><name><surname>Gilbert</surname><given-names>Luke A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-31951"><name><surname>Kampmann</surname><given-names>Martin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3819-7019</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-227035"><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-124041"><name><surname>Jost</surname><given-names>Marco</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1369-4908</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><institution content-type="dept">Medical Scientist Training Program</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>Whitehead Institute for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Cellular and Molecular Pharmacology</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Microbiology</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Center for Alzheimer's Disease and Related Dementias</institution>, <institution>National Institutes of Health</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution>National Institute of Neurological Disorders and Stroke</institution>, <addr-line><named-content content-type="city">Bethesda</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Institute for Neurodegenerative Diseases</institution>, <institution>University of California, San Francisco</institution>, <addr-line><named-content content-type="city">San Francisco</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-149894"><name><surname>Carette</surname><given-names>Jan E</given-names></name><role>Reviewing editor</role><aff><institution>Stanford University School of Medicine</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>weissman@wi.mit.edu</email> (JW);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>marco_jost@hms.harvard.edu</email> (MJ);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>12</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e81856</elocation-id><history><date date-type="received"><day>13</day><month>07</month><year>2022</year></date><date date-type="accepted"><day>23</day><month>12</month><year>2022</year></date></history><permissions><license xlink:href="http://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81856-v1.pdf"/><abstract><p>CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1-3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal nonspecific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R00GM130964</award-id><principal-award-recipient><name><surname>Jost</surname><given-names>Marco</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32AI132120</award-id><principal-award-recipient><name><surname>Russell</surname><given-names>Baylee J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000854</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><award-id>2019L/LT000858</award-id><principal-award-recipient><name><surname>Guna</surname><given-names>Alina</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014989</institution-id><institution>Chan Zuckerberg Initiative</institution></institution-wrap></funding-source><award-id>Ben Barres Early Career Acceleration Award</award-id><principal-award-recipient><name><surname>Kampmann</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000011</institution-id><institution>Howard Hughes Medical Institute</institution></institution-wrap></funding-source><award-id>Investigator</award-id><principal-award-recipient><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>RM1HG009490-01</award-id><principal-award-recipient><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>Springer Nature Global Grant for Gut Health</institution></institution-wrap></funding-source><award-id>1772808</award-id><principal-award-recipient><name><surname>Jost</surname><given-names>Marco</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001680</institution-id><institution>Charles H. Hood Foundation</institution></institution-wrap></funding-source><award-id>Child Health Research Award</award-id><principal-award-recipient><name><surname>Jost</surname><given-names>Marco</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000185</institution-id><institution>Defense Advanced Research Projects Agency</institution></institution-wrap></funding-source><award-id>HR0011-19-2-0007</award-id><principal-award-recipient><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015991</institution-id><institution>Ludwig Center for Molecular Oncology</institution></institution-wrap></funding-source><award-id>NA</award-id><principal-award-recipient><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100014989</institution-id><institution>Chan Zuckerberg Initiative</institution></institution-wrap></funding-source><award-id>NA</award-id><principal-award-recipient><name><surname>Weissman</surname><given-names>Jonathan S</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F31NS115380</award-id><principal-award-recipient><name><surname>Replogle</surname><given-names>Joseph M</given-names></name></principal-award-recipient></award-group><award-group id="par-13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>F30AG066418</award-id><principal-award-recipient><name><surname>Leng</surname><given-names>Kun</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Joseph M Replogle, consults for Maze Therapeutics and Waypoint Bio.</p></fn><fn fn-type="conflict" id="conf3"><p>Thomas M Norman, consults for Maze Therapeutics. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..</p></fn><fn fn-type="conflict" id="conf4"><p>Luke A Gilbert, declares outside interest in Chroma Medicine. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..</p></fn><fn fn-type="conflict" id="conf5"><p>Martin Kampmann, serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector, and is an advisor to Modulo Bio and Recursion Therapeutics. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..</p></fn><fn fn-type="conflict" id="conf6"><p>Jonathan S Weissman, declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..</p></fn><fn fn-type="conflict" id="conf7"><p>Marco Jost, consults for Maze Therapeutics and Gate Bioscience. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data are available on NCBI GEO under accession number GSE205310 (Perturb-seq) and GSE205147 (bulk RNA-seq). sgRNA counts from CRISPRi screens are included as supplemental tables. All data generated or analyzed during this study are included in the manuscript and supporting files.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Replogle J</collab><collab>Pogson A</collab><collab>Weissman J</collab><collab>Jost M</collab></person-group><year iso-8601-date="2022">2022</year><source>Comparison of dual sgRNA library versus Dolcetto by Perturb-seq</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205310">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205310</ext-link><comment>NCBI Gene Expression Omnibus, GSE205310</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Replogle J</collab><collab>Bonnar J</collab><collab>Weissman J</collab><collab>Jost M</collab></person-group><year iso-8601-date="2022">2022</year><source>Comparison of non-specific transcriptional effects of CRISPRi effector proteins by RNA-seq</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205147">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205147</ext-link><comment>NCBI Gene Expression Omnibus, GSE205147</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-81856-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>